Icu Medical Inc/de 8-K filings

ICU Medical announced strong second quarter 2026 results, exceeding expectations for Infusion Systems and generally meeting them for other segments, leading to an upward revision of its full-year financial guidance.

ICU Medical, Inc. announced that its stockholders approved significant amendments to its Certificate of Incorporation, including a shift to simple majority voting and a 25% threshold for calling special meetings.

ICU Medical announced its first quarter 2026 financial results, showing a GAAP revenue decline but a non-GAAP organic revenue increase, with adjusted EBITDA slightly down year-over-year.

ICU Medical announced its fourth quarter 2025 financial results, reporting a revenue decline to $540.7 million and a GAAP net loss of $(15.7) million, while providing fiscal year 2026 guidance.

ICU Medical, Inc. announced its third quarter 2025 financial results, reporting a significant reduction in GAAP net loss and an increase in adjusted diluted EPS, leading to an upward revision of its full fiscal year 2025 guidance.

ICU Medical, Inc. reported a significant swing to GAAP net income in Q2 2025, alongside improved gross margins and adjusted profitability, despite a decline in overall revenue.

ICU Medical's stockholders approved an amendment to the company's 2011 Stock Incentive Plan, increasing the number of shares available for issuance.

ICU Medical's first quarter 2025 results reveal increased revenue and improved earnings compared to the same period last year, although a GAAP net loss was still reported.

ICU Medical reports Q4 2024 revenue of $629.8 million, up from $587.9 million in the prior year, and provides FY2025 guidance with adjusted EBITDA expected to be in the range of $395 million to $425 million.

ICU Medical's third-quarter results show revenue growth but a net loss, with updated full-year guidance reflecting a wider GAAP loss range but improved adjusted earnings per share.

ICU Medical has appointed Daniel Woolson as its new President, effective immediately, as of September 30, 2024.

ICU Medical reported a revenue increase for the second quarter of 2024, but also a net loss, and updated its full-year guidance.

ICU Medical's stockholders elected all director nominees and ratified Deloitte & Touche LLP as the company's independent auditor at their annual meeting on May 15, 2024.

ICU Medical's first quarter 2024 results show a slight revenue decrease and a significant increase in net loss compared to the same period last year, though adjusted earnings per share remain positive.

William Seeger has resigned from the ICU Medical board of directors, effective immediately, following his planned retirement from Smiths Group.

ICU Medical announced its fourth quarter 2023 financial results, showing a slight revenue increase but a net loss, and provided its fiscal year 2024 guidance.